Cerevance Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03657030
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Cerevance | Cerevance Beta, Inc. | Cerevance, Inc.